Purinethol, Xaluprine (previously mercaptopurine nova laboratories)(mercaptopurine)
Purinethol, Purixan, Xaluprine (mercaptopurine) is a small molecule pharmaceutical. Mercaptopurine was first approved as Purinethol on 1982-01-01. It is used to treat b-cell chronic lymphocytic leukemia, non-hodgkin lymphoma, and precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat lymphoid leukemia.
Download report
Favorite
Drugs Approved for Childhood Cancers
Commercial
Trade Name
FDA
EMA
Purinethol, Purixan (generic drugs available since 2004-02-11)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mercaptopurine | ANDA | 2022-03-11 |
| purinethol | New Drug Application | 2021-01-15 |
| purixan | New Drug Application | 2020-04-15 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0108 | Mercaptopurine, oral, 50 mg |
Clinical
Clinical Trials
183 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | — | 23 | 28 | — | 4 | 52 | |
| Lymphoma | D008223 | C85.9 | — | 2 | 10 | — | — | 12 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 1 | 4 | — | — | 6 | |
| Philadelphia chromosome | D010677 | 2 | 4 | 2 | — | — | 6 | ||
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 2 | 2 | — | — | 4 |
| T-cell leukemia | D015458 | — | 3 | 2 | — | — | 3 | ||
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | 1 | — | 2 | 3 |
| Langerhans-cell histiocytosis | D006646 | C96.6 | — | 1 | 2 | — | — | 2 | |
| Mucositis | D052016 | EFO_1001898 | — | — | 1 | — | — | 1 | |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Biphenotypic leukemia acute | D015456 | C95.0 | 2 | 2 | — | — | — | 3 | |
| Burkitt lymphoma | D002051 | C83.7 | 1 | 1 | — | — | — | 1 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | — | 1 | — | — | — | 1 | |
| B-cell leukemia | D015448 | — | 1 | — | — | — | 1 | ||
| Neutropenia | D009503 | D70 | — | 1 | — | — | — | 1 | |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | — | — | — | 1 |
| Hermanski-pudlak syndrome | D022861 | E70.331 | — | 1 | — | — | — | 1 | |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | 1 | — | — | — | 1 |
| Lymphocytosis | D008218 | — | 1 | — | — | — | 1 | ||
| Drug evaluation | D004341 | — | 1 | — | — | — | 1 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | 3 | 3 | |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MERCAPTOPURINE |
| INN | mercaptopurine |
| Description | Purine-6-thiol is a thiol that is the tautomer of mercaptopurine. It has a role as an antineoplastic agent and an antimetabolite. It is a tautomer of a mercaptopurine. It derives from a hydride of a 7H-purine. |
| Classification | Small molecule |
| Drug class | aptamers, classical and mirror |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O.S=c1[nH]cnc2nc[nH]c12 |
Identifiers
| PDB | — |
| CAS-ID | 50-44-2 |
| RxCUI | 1546028 |
| ChEMBL ID | CHEMBL1200751 |
| ChEBI ID | 31822 |
| PubChem CID | 667490 |
| DrugBank | DB01033 |
| UNII ID | PKK6MUZ20G (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
|---|---|---|---|---|
| VCV000225201 | NUDT15, 415C>T, Arg139Cys | drug response | 2021-03-24 | 1A |
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,767 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
782 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more